Oramed Surges on New Diabetes Treatment
Market News

Oramed Surges on New Diabetes Treatment

Fighting either type of diabetes is a challenge that can follow some around for their entire lives. That’s why news out of healthcare stock Oramed Pharmaceuticals (NASDAQ:ORMP) was such a welcome development in Monday’s trading. Sufficiently welcome to send Oramed shares up over 10%.

The good news for Oramed didn’t come so much from Oramed itself as it did from its strategic partner, Hefei Tianhui Biotechnology, which completed its Phase 3 trials for a drug known as ORA-D-013-1, an oral insulin medication for treating type 2 diabetes. With the testing complete, it now goes on to the National Medical Products Administration in China, where the data generated from the study will be used as part of a marketing application to make the drug available for sale.

The study of ORA-D-013-1 revealed that, in certain populations, oral insulin can work out very nicely. One possible issue that will likely emerge is that all those involved in the testing had a similar baseline body mass index (BMI), which means they were roughly the same height and weight. Or, at least, they shared a similar ratio of height and weight. The news comes at a good time, though, at least for one person: conservative commentator Ben Shapiro, who recently put $4.8 million behind Oramed not long after Oramed revealed it was considering strategic alternatives.

It also comes at a good time for insiders. Insider trading at Oramed has been very buy-weighted in the last three months, with insiders picking up an additional $213,300 in shares. That move has swung insider sentiment to “positive” overall.

Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Oramed Surges on New Diabetes Treatment
News On DemandStay up-to-date on market-moving news with a feed made just for youGet the App

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
RUT
Russell 2000
TNX
10-Yr-Bond
Bitcoin

Popular Articles